Finance

Lists
Q3 2026 earnings • released • EPS beat +148.51% • Revenue beat +7.84%
See results
CAI:NASDAQ
Caris Life Sciences Inc
$26.03
-21.64%
(-7.19) 1D
$26.29
+1.00% (+0.26)
After hours
Closed: Nov 5, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CAI...
Open
$27.18
High
$27.76
Low
$25.30
Mkt. cap
7.36B
Avg. vol.
3.65M
Volume
7.83M
P/E ratio
70.95
52-wk high
$36.50
52-wk low
$14.19
EPS
$0.37
Shares outstanding
282.60M
No. of employees
2K
Open
$27.18
High
$27.76
Low
$25.30
Mkt. cap
7.36B
Avg. vol.
3.65M
Volume
7.83M
P/E ratio
70.95
52-wk high
$36.50
52-wk low
$14.19
EPS
$0.37
Shares outstanding
282.60M
No. of employees
2K
News stories
From web sources and news partners
About Caris Life Sciences Inc
CEO-
Employees1.85K
Founded2008
HeadquartersIrving, Texas, United States
SectorHealth Care
IndustryBiotechnology
Websitecarislifesciences.com
Analyst ratings
Based on 10 analysts giving stock ratings to CAI in the past 3 months
Buy
Buy
7
Hold
3
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for CAI in the last 3 months.
Highest
Current $26.03
$38.00 (+45.99%)
Average
$31.67 (+21.67%)
Lowest
$22.00 (-15.48%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Westenberg
Piper Sandler
Hold
Maintained
$22.00
-15.5%
11/05/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$38.00
+46%
11/05/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
$35.00
+34.5%
11/05/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$33.00
+26.8%
11/05/2026
Lu Li
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Kyle Mikson CFA
Canaccord Genuity
Hold
Maintained
$30.00
+15.3%
11/05/2026
Mark Massaro
BTIG
Buy
Maintained
$38.00
+46%
10/27/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$35.00
+34.5%
10/14/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
$35.00
+34.5%
10/09/2026
Unknown Analyst
UBS
Hold
Initiated
$28.00
+7.6%
09/08/2026
Doug Schenkel
UBS
Hold
Initiated
$28.00
+7.6%
09/09/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$26.00
-0.1%
08/06/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
06/01/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$36.00
+38.3%
05/11/2026
Patrick B Donnelly
Citi
Buy
Maintained
$28.00
+7.6%
05/08/2026
Tycho Peterson
Jefferies
Buy
Initiated
$28.00
+7.6%
04/12/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$0.05 / $0.02
+148.51%beat
Revenue / Est. (USD)
275.36M / 255.34M
+7.84%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
292.89M
216.17M
263.71M
275.36M
Cost of goods sold
70.10M
74.83M
84.12M
-
Cost of revenue
70.10M
74.83M
84.12M
-
Research and development expenses
29.82M
31.32M
32.36M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
104.55M
104.75M
120.31M
-
Operating expense
134.37M
136.07M
152.67M
-
Total operating expenses
204.48M
210.89M
236.79M
-
Operating income
88.41M
5.28M
26.93M
-
Other non operating income
-148.00K
49.00K
101.00K
-
EBT including unusual items
81.96M
-644.00K
-614.00K
-
EBT excluding unusual items
83.92M
-644.00K
24.62M
-
Income tax expense
-
-134.00K
23.00K
-
Effective tax rate
-
20.81%
-3.75%
-
Other operating expenses
-
-
-
-
Net income
81.96M
-510.00K
-637.00K
-
Net profit margin
27.98%
-0.24%
-0.24%
-
Earnings per share
0.28
-
-
0.05
Interest and investment income
7.02M
6.83M
6.82M
-
Interest expense
-11.36M
-12.81M
-9.23M
-
Net interest expenses
-4.34M
-5.98M
-2.41M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
92.70M
10.35M
33.46M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps